Blanca E. Garcia-Ocampo

Ocoyoacac, MEX 52750, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Enhancing Cytosolic Internalization of [177Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

Enhancing Cytosolic Internalization of [177Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

Journal: International journal of molecular sciences

Published: November 04, 2025

Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.

Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.

Journal: Pharmaceutics

Published: July 30, 2025

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Journal: International journal of molecular sciences

Published: June 11, 2025

Synthesis and Evaluation of [18F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [177Lu]Lu-DOTA-iPD-L1.

Synthesis and Evaluation of [18F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [177Lu]Lu-DOTA-iPD-L1.

Journal: Pharmaceutics

Published: May 30, 2025

Charge Transfer Reactions (PDT Reaction I) Induced at 1064 nm (NIR-II) between Rhodamines and Folic Acid as the Basis for Biphotonic Photodynamic Therapy.

Charge Transfer Reactions (PDT Reaction I) Induced at 1064 nm (NIR-II) between Rhodamines and Folic Acid as the Basis for Biphotonic Photodynamic Therapy.

Journal: Journal of fluorescence

Published: April 08, 2025

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Journal: Nuclear medicine and biology

Published: December 02, 2024

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Journal: EJNMMI radiopharmacy and chemistry

Published: December 02, 2024

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Journal: Pharmaceutics

Published: September 21, 2024

Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS).

Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS).

Journal: Cytotherapy

Published: June 10, 2024

An Overview of Film-Forming Emulsions for Dermal and Transdermal Drug Delivery.

An Overview of Film-Forming Emulsions for Dermal and Transdermal Drug Delivery.

Journal: AAPS PharmSciTech

Published: June 04, 2024

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

Journal: Pharmaceutics

Published: January 09, 2024

Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.

Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.

Journal: Nanomaterials (Basel, Switzerland)

Published: December 15, 2023

Showing 1-12 of 73

Last Updated: 09/26/2026